ZA202006415B - Tetrabenazine transdermal delivery device - Google Patents
Tetrabenazine transdermal delivery deviceInfo
- Publication number
- ZA202006415B ZA202006415B ZA2020/06415A ZA202006415A ZA202006415B ZA 202006415 B ZA202006415 B ZA 202006415B ZA 2020/06415 A ZA2020/06415 A ZA 2020/06415A ZA 202006415 A ZA202006415 A ZA 202006415A ZA 202006415 B ZA202006415 B ZA 202006415B
- Authority
- ZA
- South Africa
- Prior art keywords
- tetrabenazine
- transdermal delivery
- delivery device
- adhesive
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662456P | 2018-04-25 | 2018-04-25 | |
| PCT/US2019/028900 WO2019209940A1 (en) | 2018-04-25 | 2019-04-24 | Tetrabenazine transdermal delivery device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202006415B true ZA202006415B (en) | 2024-04-24 |
Family
ID=68295781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/06415A ZA202006415B (en) | 2018-04-25 | 2020-10-15 | Tetrabenazine transdermal delivery device |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12144899B2 (OSRAM) |
| EP (1) | EP3784237B1 (OSRAM) |
| JP (1) | JP7386544B2 (OSRAM) |
| KR (1) | KR102952482B1 (OSRAM) |
| CN (1) | CN112165942B (OSRAM) |
| AU (1) | AU2019261403B2 (OSRAM) |
| BR (1) | BR112020021700A2 (OSRAM) |
| CA (1) | CA3097189A1 (OSRAM) |
| DK (1) | DK3784237T3 (OSRAM) |
| ES (1) | ES2968827T3 (OSRAM) |
| IL (1) | IL278185B2 (OSRAM) |
| MX (1) | MX2020011269A (OSRAM) |
| TW (1) | TWI832854B (OSRAM) |
| WO (1) | WO2019209940A1 (OSRAM) |
| ZA (1) | ZA202006415B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3784237T3 (da) | 2018-04-25 | 2024-01-08 | Shinkei Therapeutics Inc | Indretning til transdermal levering af tetrabenazin |
| CN114828851A (zh) * | 2019-10-22 | 2022-07-29 | 新凯治疗有限责任公司 | 丁苯那嗪经皮递送装置 |
| EP4125902A4 (en) * | 2020-03-30 | 2024-05-22 | Shinkei Therapeutics, Inc. | TRANSDERMAL ADMINISTRATION OF DEXTROMETHORPHAN |
| CN116036055A (zh) * | 2023-03-16 | 2023-05-02 | 上海世领制药有限公司 | 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63313723A (ja) | 1987-06-16 | 1988-12-21 | Nitto Electric Ind Co Ltd | 外用貼付剤 |
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| JP4988080B2 (ja) * | 1997-09-05 | 2012-08-01 | 日東電工株式会社 | 経皮吸収型製剤 |
| ES2252865T3 (es) | 1997-09-26 | 2006-05-16 | Noven Pharmaceuticals, Inc. | Composiciones bioadhesivas y metodos para la administracion topica de agentes activos. |
| AU2001292781A1 (en) * | 2000-09-19 | 2002-04-02 | National Starch And Chemical Investment Holding Corporation | Acryl adhesive useful in transdermal drug delivery systems |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| MX2007004315A (es) | 2004-10-08 | 2008-03-11 | Noven Pharma | Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo. |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| GB0514501D0 (en) | 2005-07-14 | 2005-08-24 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| US20120208773A1 (en) | 2008-08-12 | 2012-08-16 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenazine |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| CA2736409C (en) | 2008-09-18 | 2017-07-11 | Auspex Pharmaceutical, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| JP2013501810A (ja) | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル（バルバドス）エスアールエル | 医薬組成物 |
| DE102010024105A1 (de) | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| PL2872126T3 (pl) * | 2012-07-16 | 2018-06-29 | Grünenthal GmbH | Plaster farmaceutyczny do przezskórnego podawania tapentadolu |
| WO2014188329A2 (en) | 2013-05-20 | 2014-11-27 | Mylan, Inc. | Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders |
| BR112015029920A2 (pt) | 2013-06-04 | 2017-07-25 | Lts Lohmann Therapie Systeme Ag | sistema de administração transdérmica |
| CA2936823A1 (en) | 2014-01-27 | 2015-07-30 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2938581C (en) | 2014-02-07 | 2023-02-28 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| HUE057839T2 (hu) | 2014-05-06 | 2022-06-28 | Neurocrine Biosciences Inc | Valbenazin adagolási rendje hiperkinetikus mozgás-zavarok kezelésére |
| AR098771A1 (es) * | 2014-12-16 | 2016-06-15 | Amarin Tech S A | Un dispositivo para la administración transdérmica de rotigotina |
| CN114767672A (zh) | 2015-03-06 | 2022-07-22 | 奥斯拜客斯制药有限公司 | 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 |
| WO2016210180A2 (en) | 2015-06-23 | 2016-12-29 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors for treating neurological diseases or disorders |
| AU2016288188B2 (en) | 2015-06-27 | 2021-08-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| CN107028916B (zh) * | 2016-02-04 | 2020-05-12 | 北京泰德制药股份有限公司 | 含有布比卡因或其药用盐的皮肤外用制剂 |
| ITUB20161016A1 (it) * | 2016-02-24 | 2017-08-24 | Emenem Srl | Composizioni farmaceutiche o cosmetiche comprendenti un polimero e un promotore di assorbimento per il rilascio controllato di principi attivi |
| PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
| KR20230169457A (ko) | 2017-01-27 | 2023-12-15 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| US20190111035A1 (en) | 2017-04-01 | 2019-04-18 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| CA3057543A1 (en) | 2017-04-01 | 2018-10-04 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder |
| US20200179352A1 (en) | 2017-04-26 | 2020-06-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| US11179469B2 (en) * | 2017-04-28 | 2021-11-23 | Nitto Denko Corporation | Transdermal absorption preparation |
| EP3664787B1 (en) | 2017-07-20 | 2022-07-20 | Neurolixis | Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors |
| GB2565049B (en) | 2017-07-27 | 2020-06-10 | Reckitt Benckiser Health Ltd | A head assembly of a dermaplaning device |
| MX2020003421A (es) | 2017-10-10 | 2020-07-20 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). |
| DK3784237T3 (da) | 2018-04-25 | 2024-01-08 | Shinkei Therapeutics Inc | Indretning til transdermal levering af tetrabenazin |
| US20190374521A1 (en) | 2018-06-10 | 2019-12-12 | Axsome Therapeutics, Inc. | Methods of modulating tetrabenazine metabolites plasma levels using bupropion |
| EP3806856A1 (en) | 2018-06-14 | 2021-04-21 | Neurocrine Biosciences, Inc. | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
-
2019
- 2019-04-24 DK DK19792500.1T patent/DK3784237T3/da active
- 2019-04-24 WO PCT/US2019/028900 patent/WO2019209940A1/en not_active Ceased
- 2019-04-24 IL IL278185A patent/IL278185B2/en unknown
- 2019-04-24 TW TW108114349A patent/TWI832854B/zh active
- 2019-04-24 EP EP19792500.1A patent/EP3784237B1/en active Active
- 2019-04-24 CN CN201980035258.6A patent/CN112165942B/zh active Active
- 2019-04-24 JP JP2020559388A patent/JP7386544B2/ja active Active
- 2019-04-24 KR KR1020207032380A patent/KR102952482B1/ko active Active
- 2019-04-24 US US17/050,230 patent/US12144899B2/en active Active
- 2019-04-24 AU AU2019261403A patent/AU2019261403B2/en active Active
- 2019-04-24 ES ES19792500T patent/ES2968827T3/es active Active
- 2019-04-24 CA CA3097189A patent/CA3097189A1/en active Pending
- 2019-04-24 BR BR112020021700-0A patent/BR112020021700A2/pt unknown
- 2019-04-24 MX MX2020011269A patent/MX2020011269A/es unknown
-
2020
- 2020-10-15 ZA ZA2020/06415A patent/ZA202006415B/en unknown
-
2024
- 2024-10-10 US US18/911,581 patent/US20250144045A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019261403A1 (en) | 2020-11-12 |
| DK3784237T3 (da) | 2024-01-08 |
| US20250144045A1 (en) | 2025-05-08 |
| WO2019209940A1 (en) | 2019-10-31 |
| CN112165942A (zh) | 2021-01-01 |
| JP7386544B2 (ja) | 2023-11-27 |
| BR112020021700A2 (pt) | 2021-01-26 |
| MX2020011269A (es) | 2020-12-11 |
| CN112165942B (zh) | 2024-04-12 |
| KR102952482B1 (ko) | 2026-04-13 |
| AU2019261403B2 (en) | 2025-05-15 |
| TW202014187A (zh) | 2020-04-16 |
| US20210128490A1 (en) | 2021-05-06 |
| TWI832854B (zh) | 2024-02-21 |
| EP3784237A1 (en) | 2021-03-03 |
| EP3784237A4 (en) | 2022-02-16 |
| KR20210005623A (ko) | 2021-01-14 |
| ES2968827T3 (es) | 2024-05-14 |
| IL278185A (OSRAM) | 2020-12-31 |
| US12144899B2 (en) | 2024-11-19 |
| JP2021522240A (ja) | 2021-08-30 |
| CA3097189A1 (en) | 2019-10-31 |
| IL278185B2 (en) | 2024-11-01 |
| IL278185B1 (en) | 2024-07-01 |
| EP3784237B1 (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502738A1 (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| MX2022010168A (es) | Moduladores de calpainas y usos terapeuticos de los mismos. | |
| EP4349735A3 (en) | Packages for medical devices | |
| MX2020011269A (es) | Dispositivo de administración transdérmica de tetrabenazina. | |
| MX2018008190A (es) | Sistemas y metodos para la administracion transdermica a largo plazo. | |
| CY1122716T1 (el) | Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας | |
| MX2017003623A (es) | Parche de opipramol. | |
| BR112018008103A2 (pt) | análogos de celastrol | |
| DK3706841T3 (da) | Kanyleskjoldsfjerner og medikamentafgivelsesindretning, der omfatter kanyleskjoldsfjerneren | |
| MX391117B (es) | Inhibidores de magl. | |
| BR112016001781A2 (pt) | inibidores de rorc2 e métodos de uso dos mesmos | |
| MX2021006102A (es) | Suministro mejorado de agentes grandes. | |
| EP3691641A4 (en) | DEXTROMETHORPHANE DEVICE FOR TRANSDERMAL ADMINISTRATION | |
| MX372702B (es) | Una composicion antimicrobiana. | |
| FI20165932L (fi) | Immunomodulatorisia koostumuksia | |
| PH12017550005A1 (en) | Drug-device unit containing quinagolide | |
| AU2017394032A8 (en) | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome | |
| EP3389760A4 (en) | ELECTROKINETIC TRANSDERMAL AND TRANSMUCOSAL DELIVERY DEVICE | |
| EP3434314A4 (en) | TRANSDERMAL DELIVERY SYSTEM | |
| EP3846885B8 (en) | Medicament delivery device | |
| EP4048268A4 (en) | DEVICE FOR TRANSDERMAL ADMINISTRATION OF TETRABENAZINE | |
| GEAP202115006A (en) | Combination of bcl-2 inhibitor and mcl-1 inhibitor, uses and pharmaceutical compositions thereof | |
| MX2017001651A (es) | Peptido derivado de urlc10 y vacuna que lo contiene. | |
| MX2018009739A (es) | La administración combinada de un agente de penetración y un compuesto que contiene azufre a plantas. | |
| PH12017501563A1 (en) | Oligomeric/polymeric silicone fluids for use in transdermal drug delivery systems |